Trial · NCT07507188
Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)
NCT07507188, Phase 2, Not yet recruiting, Yonsei University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study). Trials, record NCT07507188. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07507188
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)
- NCT number
- NCT07507188
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Yonsei University
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Amivantamab SC + Lazertinib PO, Amivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV)
- First posted
- 2026-04-02
- Last updated
- 2026-04-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | • scRNA-seq and/or spatial RNA sequencing analysis. Multiplex IHC and/or FACS analysis. | through study completion, an average of 5 year | • Molecular candidates associated with the activity of amivantamab-based regimens identified by analyzing scRNA-seq and/or spatial RNA sequencing from pre-treatment tumor biopsy specimens and tumor tissue acquired at the time of C3D1. Multiplex IHC and/or FACS analysis performed either pre-treatment or post-treatment. |
| Secondary | Objective Response rate (ORR) | through study completion, an average of 5 year | Objective Response rate (ORR): the proportion of participants who achieve a CR or PR, based on RECIST v1.1. |
| Secondary | Progression-free survival (PFS) | through study completion, an average of 5 year | Progression-free survival (PFS): the time from the first dose of study treatment until the date of objective disease progression or death, whichever comes first, based on RECIST v1.1. |
| Secondary | Duration of response (DoR) | through study completion, an average of 5 year | Duration of response (DoR): the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR |
| Secondary | circulating tumor DNA (ctDNA). | through study completion, an average of 5 year | To assess EGFR mutations, MET alterations, and mutations in other key oncogenes, samples for ctDNA analysis will be collected |
| Other | Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment (TRAE, Clinical laboratory test, Vital signs, Physical Examination, Weight) | through study completion, an average of 5 year | Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment (TRAE, Clinical laboratory test, Vital signs, Physical Examination, Weight) |
| Other | The biomarker and ctDNA samples. | through study completion, an average of 5 year | The biomarker and ctDNA samples may be used to explore the potential to predict clinical benefit, relapse, and/or identify mechanism of resistance to assigned treatment, and to enable the development of safer, more effective, and ultimately individualized therapies. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07507188
GET https://conductscience.org/api/trials/v1/NCT07507188/registered